Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae | Zendy

David van Duin | Zendy; Judith J. Lok | Zendy; Michelle Earley | Zendy; Eric Cober | Zendy; Sandra S. Richter | Zendy; Federico Pérez | Zendy; Robert A. Salata | Zendy; Robert C. Kalayjian | Zendy; Richard Watkins | Zendy; Yohei Doi | Zendy; Keith S. Kaye | Zendy; Vance G. Fowler | Zendy; David L. Paterson | Zendy; Robert A. Bonomo | Zendy; Scott Evans | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae

Author(s) -

David van Duin,

Judith J. Lok,

Michelle Earley,

Eric Cober,

Sandra S. Richter,

Federico Pérez,

Robert A. Salata,

Robert C. Kalayjian,

Richard Watkins,

Yohei Doi,

Keith S. Kaye,

Vance G. Fowler,

David L. Paterson,

Robert A. Bonomo,

Scott Evans

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix783

Subject(s) - ceftazidime/avibactam , colistin , medicine , enterobacteriaceae , ceftazidime , carbapenem resistant enterobacteriaceae , enterobacteriaceae infections , microbiology and biotechnology , avibactam , carbapenem , antibiotics , pseudomonas aeruginosa , biology , bacteria , escherichia coli , biochemistry , genetics , gene

The efficacy of ceftazidime-avibactam-a cephalosporin-β-lactamase inhibitor combination with in vitro activity against Klebsiella pneumoniae carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CRE)-compared with colistin remains unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research